Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...
Neuroscience
New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...
New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations
Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read...
Precision Neuroscience Acquires U.S. Manufacturing Facility and Receives FDA Breakthrough Device Designation
The purchase allows the brain–computer interface company to oversee the end-to-end fabrication of its microelectrode array while iterating quickly on...
Synchrony Symposium 2023 Advances Research and Clinical Care for Neurodevelopmental Disorders, Including Autism
Dr. Mario Capecchi, Nobel Laureate at University of Utah, to Deliver Keynote on Research to Understand Symptoms Prevalent in Individuals...
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile...
BrainsWay Announces Presentation of Two Deep TMS™ Posters at Upcoming World Congress of Psychiatry
Preliminary Research on Late Life Depression and Accelerated Depression Treatment Protocol will be FeaturedBURLINGTON, Mass. and JERUSALEM, Sept. 27, 2023...
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral...
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed...
Brain Canada’s flagship program awards $2.8 million for brain research
Brain Canada’s Future Leaders in Canadian Brain Research program to support 28 early-career researchers this year The 2022 Future Leaders...
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British...
Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100
Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical researchDURHAM, N.C., Sept. 20, 2023...
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,...
Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity
Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and...
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
Purchases All 5,323,451 Shares Validly Tendered at $0.70 per SharePALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) --...
Cognetivity Neurosciences’ AI Powered CognICA Platform Wins Major Industry Award
CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX FestivalVancouver, British Columbia--(Newsfile Corp. - September 13,...
Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference
-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science...
Neuroscience Center in Sweden Orders Nexstim NBS 5 System
Press release, Helsinki, 13 September 2023 at 10 AM (EEST) Neuroscience Center in Sweden Orders Nexstim NBS 5 System Nexstim...
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ETVANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE)...